Novartis Heart Drug Fails Major Trial, Raising Questions Over Lp(a) Treatment
Novartis and Ionis Pharmaceuticals' experimental heart drug pelacarsen failed to meet its primary goal in a late-stage trial, despite reducing Lp(a) levels. The drug did not significantly lower major cardiovascular events, raising questions about Lp(a) treatment. Novartis shares fell 5% and Ionis shares dropped 12% in after-hours trading. The companies will present detailed results at an upcoming medical congress.
How this was made
The 30-second read
Why it matters
The trial failed to show a statistically significant reduction in heart attacks or strokes despite lowering Lp(a), raising doubts about the therapeutic hypothesis.
Market read
The negative data could depress both companies' stocks and influence investor sentiment toward other Lp(a) programs.
What to watch
Regulatory pathways and potential combination therapies could mitigate the setback.
Background
Novartis and Ionis were testing pelacarsen, an antisense oligonucleotide aimed at lowering Lp(a) to reduce cardiovascular events.
Ticker impact
Novartis shares fell about 5% after the failed Phase 3 trial of pelacarsen.
Expect further downside of 3‑5% in the next trading session.
The trial was large (8,000+ patients) and the stock already dropped 5% in after‑hours; market reaction typically continues into regular trading.
Market effects
Lipoprotein(a) lowering strategies face heightened scrutiny, potentially affecting other Lp(a) drug developers.
European and US biotech indices may see modest declines.
Limited to cardiovascular biotech segment; broader market impact minimal.
Counterpoint
If the Lp(a) reduction is clinically meaningful long‑term, the market may overreact now.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant developing pelacarsen.
- CompanyIonis Pharmaceuticals
US biotech partner in the pelacarsen program.
